Pharmacology of formoterol: an innovative bronchodilator
- PMID: 1686531
Pharmacology of formoterol: an innovative bronchodilator
Abstract
Formoterol is an innovative, highly potent, beta-2 selective adrenoceptor agonist combining the clinical advantages of rapid onset of action with a duration of action in excess of 12 h. In vitro, formoterol is a potent airway smooth muscle relaxant with high intrinsic activity. Formoterol appears to be retained in airway smooth muscle for extended periods since its relaxant effect on human airway smooth muscle is resistant to repeated washing and formoterol displays "reassertion" of relaxation after washout of a beta-adrenoceptor antagonist. In addition to airway smooth muscle relaxation, formoterol inhibits a range of acute inflammatory processes in animal models including eosinophil activation and infiltration of the airways, microvascular leakage, and antigen-induced mediator release from human lung. Whether these non-airway smooth muscle effects may influence chronic airway inflammation in clinical asthma remains to be determined.
Similar articles
-
Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator.Life Sci. 1993;52(26):2145-60. doi: 10.1016/0024-3205(93)90729-m. Life Sci. 1993. PMID: 8099696 Review.
-
Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction.Pulm Pharmacol Ther. 2002;15(4):399-406. doi: 10.1006/pupt.2002.0366. Pulm Pharmacol Ther. 2002. PMID: 12220946 Clinical Trial.
-
Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol.Agents Actions Suppl. 1993;43:253-69. doi: 10.1007/978-3-0348-7324-6_22. Agents Actions Suppl. 1993. PMID: 8103622
-
The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus.Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):405-9. doi: 10.1007/s002109900213. Naunyn Schmiedebergs Arch Pharmacol. 2000. PMID: 10763855
-
Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.Lung. 1996;174(1):1-22. doi: 10.1007/BF00167947. Lung. 1996. PMID: 8746998 Review.
Cited by
-
Mechanistic analysis of Th2-type inflammatory factors in asthma.J Thorac Dis. 2023 Dec 30;15(12):6898-6914. doi: 10.21037/jtd-23-1628. Epub 2023 Dec 26. J Thorac Dis. 2023. PMID: 38249931 Free PMC article.
-
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity.Exp Ther Med. 2011 Jul;2(4):731-735. doi: 10.3892/etm.2011.260. Epub 2011 Apr 28. Exp Ther Med. 2011. PMID: 22977567 Free PMC article.
-
Comparison of the Bronchodilator Effect of Inhaled Short- and Long-Acting beta(2)-Agonists in Children with Bronchial Asthma: A Randomised Trial.Clin Drug Investig. 1998;16(1):19-24. doi: 10.2165/00044011-199816010-00003. Clin Drug Investig. 1998. PMID: 18370514
-
Long- versus short-acting beta 2-agonists. Implications for drug therapy.Drugs. 1994 Feb;47(2):207-22. doi: 10.2165/00003495-199447020-00001. Drugs. 1994. PMID: 7512898 Review. No abstract available.
-
Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.Br J Pharmacol. 1993 Oct;110(2):613-8. doi: 10.1111/j.1476-5381.1993.tb13855.x. Br J Pharmacol. 1993. PMID: 7902175 Free PMC article.